58 results
8-K
UBX
Unity Biotechnology Inc
16 Sep 20
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
4:49pm
was the Corporate Controller for Kythera Biopharmaceuticals, Inc. after it was acquired by Allergan plc., where he had responsibility for the company’s … and acquisitions. From 2003 to 2013, he held roles of increasing responsibility in Ernst & Young’s audit practice, serving clients in the life sciences sector
8-K
UBX
Unity Biotechnology Inc
6 Jul 20
Departure of Directors or Certain Officers
5:15pm
, Ms. Sullivan had global responsibility for Biogen’s Financial Planning & Analysis, Corporate Tax, and Corporate Finance groups, which included
424B5
UBX
Unity Biotechnology Inc
7 Jun 19
Prospectus supplement for primary offering
5:01pm
prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and Cowen take no responsibility … writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance
DEF 14A
UBX
Unity Biotechnology Inc
26 Apr 19
Definitive proxy
5:27pm
roles of increasing responsibility at Amgen from 1994 to 2011, including as Senior Vice President of Research. Dr. Lacey currently serves on the board … of increasing responsibility at Deutsche Bank Securities, an investment bank, from August 1997 to February 2006, including Director, Health Care Investment
424B5
etz7crz2c 4j
31 Jul 20
Prospectus supplement for primary offering
9:18am
8-K
EX-1.1
3ei2yf hm
19 Aug 22
Other Events
8:39am
424B5
qvzythr
19 Aug 22
Prospectus supplement for primary offering
8:37am
424B5
ejjtpkx
13 May 22
Prospectus supplement for primary offering
4:18pm
424B5
jnxpsi1zfjq
25 Oct 22
Prospectus supplement for primary offering
9:39pm
S-3
0z57cp
3 Jun 19
Shelf registration
9:18am
424B5
h73b263g np4p69q
16 Aug 22
Prospectus supplement for primary offering
5:26pm
424B5
0l7 mroul
29 Sep 21
Prospectus supplement for primary offering
5:24pm
10-K
EX-10.22
1d25rqjw3ic0 8bq
6 Mar 19
Annual report
8:06am
424B5
69xe0c3sf8jgi
19 Aug 22
Prospectus supplement for primary offering
8:42am